Skip to main content
SpringerLink
Log in

Expression and prognostic value of plasminogen activator inhibitor type 1 in node-negative breast cancer

  • Published:
The Chinese-German Journal of Clinical Oncology

Abstract

Objective

To investigate the expressions of plasminogen activator inhibitor type 1 (PAI-1), C-erbB-2, VEGF and Ki-67 by immunohistostaining and then to evaluate the prognostic value of PAI-1 in node-negative breast cancer.

Methods

The study included a retrospective series of 62 female patients with axillary lymph node-negative breast cancer. Expressions of PAI-1, C-erbB-2, VEGF and Ki-67 were determined by immunohistostaining on formalin-fixed paraffin-embedded tissue sections from these patients after a median follow-up of 69 months (range 22–117 months). Correlations with well known clinicopathologic factors were assessed and multivariate survival analyses were performed.

Results

High PAI-1 level was positively associated with high histologic grade of the tumors. Disease-free survival (DFS) was significantly shorter for the patients with moderate to intensive expression of PAI-1 than for those with negative (χ2 = 25.46, P < 0.001; χ2 = 23.07, P < 0.001) to mild expression (χ2 = 19.75, P < 0.001; χ2 = 17.40, P < 0.001). Although on univariate analysis of the prognostic factors, tumor size, location of primary tumor and age as well as expressions of PAI-1, VEGF and Ki-67 were all significantly prognostic factors for DFS (P < 0.05), PAI-1 was the only independent prognostic factor on multivariate analysis (P < 0.0001; hazard ratio [HR], 4.041; 95% confidence interval [CI], 1.928–8.468).

Conclusion

These results of the current study indicate that intermediate or high expression of PAI-1 represents a strong and independent unfavorable prognostic factor for the development of recurrence or metastases in axillary node-negative breast cancer.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. Ross JS, Linette GP, Stec J, et al. Breast cancer biomarkers and molecular medicine: part II. Expert Rev Mol Diagn, 2004, 4: 169–188.

    Article  PubMed  CAS  Google Scholar 

  2. Cianfrocca M, Goldstein LJ. Prognostic and predictive factors in early-stage breast cancer. Oncologist, 2004, 9: 606–616.

    Article  PubMed  Google Scholar 

  3. Stefansson S, McMahon GA, Petitclerc E, et al. Plasminogen activator inhibitor-1 in tumor growth, angiogenesis and vascular remodeling. Curr Pharm Des, 2003, 9: 1545–1564.

    Article  PubMed  CAS  Google Scholar 

  4. Look MP, van Putten WL, Duffy MJ, et al. Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients. J Natl Cancer Inst, 2002, 94: 116–128.

    PubMed  CAS  Google Scholar 

  5. Jänicke F, Prechtl A, Thomssen C, et al. Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1. J Natl Cancer Inst, 2001, 93: 913–920.

    Article  PubMed  Google Scholar 

  6. Foekens JA, Peters HA, Look MP, et al. The urokinase system of plasminogen activation and prognosis in 2780 breast cancer patients. Cancer Res, 2000, 60: 636–643.

    PubMed  CAS  Google Scholar 

  7. Hansen S, Overgaard J, Rose C, et al. Independent prognostic value of angiogenesis and the level of plasminogen activator inhibitor type 1 in breast cancer patients. Br J Cancer, 2003, 88: 102–108.

    Article  PubMed  CAS  Google Scholar 

  8. Sweep CG, Geurts-Moespot J, Grebenschikov N, et al. External quality assessment of trans-European multicentre antigen determinations (enzyme-linked immunosorbent assay) of urokinase-type plasminogen activator (uPA) and its type 1 inhibitor (PAI-1) in human breast cancer tissue extracts. Br J Cancer, 1998, 78: 1434–1441.

    PubMed  CAS  Google Scholar 

  9. Ferrier CM, de Witte HH, Straatman H, et al. Comparison of immunohistochemistry with immunoassay (ELISA) for the detection of components of the plasminogen activation system in human tumour tissue. Br J Cancer, 1999, 79: 1534–1541.

    Article  PubMed  CAS  Google Scholar 

  10. Kaplan EL, Meier P. Nonparametric estimation from incomplete observations. J Amer Stat Assoc, 1958, 53: 457–481.

    Article  Google Scholar 

  11. Peto R, Pike MC, Armitage P, et al. Design and analysis of randomized clinical trials requiring prolonged observation of each patient. II. analysis and examples. Br J Cancer, 1977, 35: 1–39.

    PubMed  CAS  Google Scholar 

  12. Cox DR. Regression models and life-tables. J R Stat Soc, 1972, 34: 187–220.

    Google Scholar 

  13. Reuning U, Magdolen V, Wilhelm O, et al. Multifunctional potential of the plasminogen activation system in tumor invasion and metastasis (review). Int J Oncol, 1998, 13: 893–906.

    PubMed  CAS  Google Scholar 

  14. Jänicke F, Schmitt M, Pache L, et al. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat, 1993, 24: 195–208.

    Article  PubMed  Google Scholar 

  15. Stephenson J. Study indicates utility for new breast cancer prognostic marker. JAMA, 2001, 285: 3077–3078.

    Article  PubMed  CAS  Google Scholar 

  16. Ruiter DJ, Ferrier CM, van Muijen GN, et al. Quality control of immunohistochemical evaluation of tumour-associated plasminogen activators and related components. European BIOMED-1 Concerted Action on Clinical Relevance of Proteases in Tumour Invasion and Metastasis. Eur J Cancer, 1998, 34: 1334–1340.

    Article  PubMed  CAS  Google Scholar 

  17. Ferrier CM, van Geloof WL, de Witte HH, et al. Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. J Histochem Cytochem, 1998, 46: 469–476.

    PubMed  CAS  Google Scholar 

  18. Dublin E, Hanby A, Patel NK, et al. Immunohistochemical expression of uPA, uPAR, and PAI-1 in breast carcinoma. Fibroblastic expression has strong associations with tumor pathology. Am J Pathol, 2000, 157: 1219–1227.

    PubMed  CAS  Google Scholar 

  19. Jahkola T, Toivonen T, von Smitten K, et al. Cathepsin-D, urokinase plasminogen activator and type-1 plasminogen activator inhibitor in early breast cancer: an immunohistochemical study of prognostic value and relations to tenascin-C and other factors. Br J Cancer, 1999, 80: 167–174.

    Article  PubMed  CAS  Google Scholar 

  20. Heiss MM, Babic R, Allgayer H, et al. Tumor-associated proteolysis and prognosis: new functional risk factors in gastric cancer defined by the urokinase-type plasminogen activator system. J Clin Oncol, 1995, 13: 2084–2093.

    PubMed  CAS  Google Scholar 

  21. Fujii T, Obara T, Tanno S, et al. Urokinase-type plasminogen activator and plasminogen activator inhibitor-1 as a prognostic factor in human colorectal carcinomas. Hepatogastroenterology, 1999, 46: 2299–2308.

    PubMed  CAS  Google Scholar 

  22. Rosen PP, Lesser ML, Arroyo CD, et al. Immunohistochemical detection of HER2/neu in patients with axillary lymph node negative breast carcinoma. A study of epidemiologic risk factors, histologic features, and prognosis. Cancer, 1995, 75: 1320–1326.

    Article  PubMed  CAS  Google Scholar 

  23. Zemzoum I, Kates RE, Ross JS, et al. Invasion factors uPA/PAI-1 and HER2 status provide independent and complementary information on patient outcome in node-negative breast cancer. J Clin Oncol, 2003, 21: 1022–1028.

    Article  PubMed  CAS  Google Scholar 

  24. Press MF, Bernstein L, Thomas PA, et al. HER-2/neu gene amplification characterized by fluorescence in situ hybridization: poor prognosis in node-negative breast carcinomas. J Clin Oncol, 1997, 15: 2894–2904.

    PubMed  CAS  Google Scholar 

  25. Harbeck N, Ross JS, Yurdseven S, et al. HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer. Int J Oncol, 1999, 14: 663–671.

    PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Oncology, Changhai Hospital, The Second Military Medical University, Shanghai, 200433, China

    Bin Wang, Ning Wang, Chunyan Xue & Yajie Wang

  2. Department of Oncology, The Third People’s Hospital Affiliated to Jiao Tong University, Shanghai, 201900, China

    Bin Jiang

Authors
  1. Bin Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ning Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Chunyan Xue
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Bin Jiang
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Yajie Wang
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Yajie Wang.

Additional information

Supported by Research Programme of the Shanghai Municipal Science and Technology Commission (No. 06DZ19505).

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wang, B., Wang, N., Xue, C. et al. Expression and prognostic value of plasminogen activator inhibitor type 1 in node-negative breast cancer. Chin. -Ger. J. Clin. Oncol. 7, 339–343 (2008). https://doi.org/10.1007/s10330-008-0030-2

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10330-008-0030-2

Key words

Search

Navigation